GSK Dirección

Dirección controles de criterios 2/4

El CEO de GSK's es Emma Walmsley , nombrado en Apr 2017, tiene una permanencia de 7.25 años. compensación anual total es £12.72M, compuesta por 10.3% salario y 89.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.049% de las acciones de la empresa, por valor de £32.50M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 3.4 años, respectivamente.

Información clave

Emma Walmsley

Chief Executive Officer (CEO)

UK£12.7m

Compensación total

Porcentaje del salario del CEO	10.3%
Permanencia del CEO	7.1yrs
Participación del CEO	0.05%
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Emma Walmsley en comparación con los beneficios de GSK?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

Compensación vs. Mercado: La compensación total de Emma($USD15.85M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD5.61M).

Compensación vs. Ingresos: La compensación de Emma ha aumentado más de un 20% en el último año.

CEO

Emma Walmsley (54 yo)

7.1yrs

Permanencia

UK£12,718,000

Compensación

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Emma Walmsley	CEO & Director	7.1yrs	UK£12.72m	0.049% £ 34.3m
Julie Brown	CFO & Executive Director	1.1yrs	UK£5.14m	0.0024% £ 1.7m
Shobie Ramakrishnan	Chief Digital & Technology Officer	3.3yrs	sin datos	sin datos
Tony Wood	Chief Scientific Officer and Head of R&D	1.8yrs	sin datos	sin datos
Sarah Elton-Farr	Head of Investor Relations	no data	sin datos	sin datos
James Ford	Senior VP & Group General Counsel of Legal & Compliance	5.8yrs	sin datos	sin datos
Sally Jackson	Senior Vice President of Global Communications & CEO Office	5.2yrs	sin datos	sin datos
David Redfern	President of Corporate Development	no data	sin datos	sin datos
Diana Conrad	Chief People Officer	5.1yrs	sin datos	sin datos
Philip Thomson	President of Global Affairs	7.1yrs	sin datos	0.0056% £ 3.9m
Luke Miels	Chief Commercial Officer	6.7yrs	sin datos	sin datos
Kevin Sin	Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development	5.9yrs	sin datos	sin datos

5.5yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GSK es experimentado (5.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Emma Walmsley	CEO & Director	7.3yrs	UK£12.72m	0.049% £ 34.3m
Julie Brown	CFO & Executive Director	less than a year	UK£5.14m	0.0024% £ 1.7m
Jonathan Symonds	Non-Executive Chairman	4.7yrs	UK£765.00k	0.0017% £ 1.2m
Urs Rohner	Independent Non-Executive Director	9.3yrs	UK£201.00k	0.00042% £ 296.1k
Vishal Sikka	Independent Non-Executive Director	1.8yrs	UK£147.00k	0.00022% £ 155.1k
Hal Barron	Non-Executive Director	6.3yrs	UK£356.92k	0.032% £ 22.2m
Harry Dietz	Independent Non-Executive Director	2.3yrs	UK£207.09k	0.00013% £ 91.6k
Anne Beal	Independent Non-Executive Director	3yrs	UK£174.93k	0.00014% £ 98.7k
Wendy Becker	Independent Non-Executive Director	less than a year	UK£32.00k	0.000010% £ 7.0k
Charles Bancroft	Senior Independent Non-Executive Director	4yrs	UK£323.00k	0.0012% £ 817.7k
Elizabeth Anderson	Independent Non-Executive Director	1.7yrs	UK£127.86k	0.000060% £ 42.3k
Jesse Goodman	Independent Non-Executive Director	8.3yrs	UK£173.36k	0.00069% £ 486.4k

3.5yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de GSK se considera experimentada (3.4 años de antigüedad promedio).

GSK Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc Announces Board Changes

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of UK£0.16 announced

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

Price target increased by 10% to UK£19.22

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

GSK plc to Report Q4, 2023 Results on Jan 31, 2024

GSK plc (LSE:GSK) entered into an agreement to acquire Aiolos Bio, Inc. from a group of shareholders for $1.4 billion.

Insufficient Growth At GSK plc (LON:GSK) Hampers Share Price

GSK plc Announces Positive Headline Results from Planned Analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III Trial

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Gsk plc Announces It's Jemperli (Dostarlimab) Plus Chemotherapy Approved as the First and Only Frontline Immuno-Oncology Treatment in the European Union for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK Receives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia

Upcoming dividend of UK£0.14 per share at 4.3% yield

GSK (LON:GSK) Has Announced A Dividend Of £0.14

Gsk plc Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gsk plc Announces Positive Headline Results from Planned Analysis of Part 1 of the Ruby/Engot-En6/Gog3031/Nsgo Phase Iii Trial

GSK plc Announces Positive Preliminary Results from its Phase III Trial Evaluating the Immune Response and Safety of Arexvy

GSK plc Receives Positive CHMP Opinion Recommending Approval of Jemperli (Dostarlimab) Plus Chemotherapy as A New Frontline Treatment for DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Update on Zantac (Ranitidine) Litigation

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

GSK plc to Report Q3, 2023 Results on Nov 01, 2023

Is GSK (LON:GSK) A Risky Investment?

GSK plc Announces Board Changes

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Approves Arexvy for the Prevention of RSV

US Food and Drug Administration Approves GSK Plc's Ojjaara (Momelotinib) for the Treatment of Intermediate or High-Risk Myelofibrosis, Including Primary Myelofibrosis or Secondary Myelofibrosis

GSK Regulatory Submission for Momelotinib for the Treatment of Myelofibrosis Accepted for Review by Japanese Regulator

Gsk plc Announces Nucala Crswnp Submission Accepted in Japan

GSK plc Announces Positive Results from the First-Ever Efficacy Trial of Shingrix in China

GSK plc Announces AREXVY, Respiratory Syncytial Virus Vaccine, Available At All Major US Retail Pharmacies

Upcoming dividend of UK£0.14 per share at 4.4% yield

GSK plc Announced That the US Food and Drug Administration Approved Jemperli (Dostarlimab) in Combination with Carboplatin and Paclitaxe

GSK plc Announces Dividend for Second Quarter of 2023, Payable on 12 October 2023

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad